Climb Bio to Present at Upcoming Investor Conferences

Rhea-AI Summary

Climb Bio (Nasdaq: CLYM) announced that executives will participate in three investor conferences in November–December 2025: Guggenheim's 2nd Annual Healthcare Innovation Conference in Boston on Nov 10, 2025 at 11:30 a.m. ET, Baird Biotech Discovery Series (virtual) on Nov 18, 2025 at 1:30 p.m. ET, and Piper Sandler’s 37th Annual Healthcare Conference in New York on Dec 2, 2025 at 9:30 a.m. ET.

Each appearance will include fireside chats; select events include one-on-one investor meetings. Live webcasts and replay recordings will be available via the Investors & Media section of the Climb Bio website and will be archived for at least 30 days.

WELLESLEY HILLS, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that members of its executive team will participate in the upcoming investor conferences detailed below.

Guggenheim's 2nd Annual Healthcare Innovation Conference
Location: Boston
Format: Fireside chat and one-on-one investor meetings
Date: Monday, November 10, 2025
Time: 11:30 a.m. ET

Baird Biotech Discovery Series
Location: Virtual
Format: Fireside chat
Date: Tuesday, November 18, 2025
Time: 1:30 p.m. ET

Piper Sandler’s 37th Annual Healthcare Conference
Location: New York, NY
Format: Fireside chat and one-on-one investor meetings
Date: Tuesday, December 2, 2025
Time: 9:30 a.m. ET

The live webcasts will be accessible via the “Investors & Media” section of the Climb Bio website. Webcast replays will be available on the Climb Bio website beginning approximately two hours after each webcast event and will be archived for at least 30 days.

About Climb Bio, Inc.
Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody in development for IgA nephropathy. For more information, please visit climbbio.com. 

Investors and Media
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com

FAQ

When will Climb Bio (CLYM) present at Guggenheim's 2nd Annual Healthcare Innovation Conference?

Climb Bio is scheduled to present on November 10, 2025 at 11:30 a.m. ET in Boston.

How can investors watch Climb Bio's (CLYM) webcast for the Baird Biotech Discovery Series?

The Baird presentation on November 18, 2025 at 1:30 p.m. ET will be streamed via the company's Investors & Media website section.

Will Climb Bio (CLYM) attend Piper Sandler’s 37th Annual Healthcare Conference in person?

Yes; executives will attend in New York with a fireside chat and one-on-one investor meetings on December 2, 2025 at 9:30 a.m. ET.

When will Climb Bio post replays of the investor conference webcasts?

Webcast replays will be available approximately two hours after each event and will be archived for at least 30 days on the investor website.

What formats will Climb Bio (CLYM) use at the upcoming investor conferences?

Presentations will include fireside chats, and select events will feature one-on-one investor meetings.

Where on the Climb Bio website can investors find the live webcasts and replays?

Live webcasts and replays will be accessible via the website's Investors & Media section.